The Life Sciences team advised Neuroelectrics on its $17.5 million Series A financing led by Morningside Ventures.
Neuroelectrics is developing a therapeutic platform that uses neuromodulation for the treatment of a range of neurological and psychiatric disorders. The platform combines safe and proven neuromodulation capabilities with remote-controlled delivery and personalized treatment protocols to restore and maintain brain health.
Morningside Group invests private equity and venture capital in novel science and technology sectors and is committed to social responsibility.
The funds will be used to further develop Neuroelectrics’ non-invasive transcranial electrical stimulation (tES) therapeutic platform and to advance clinical trials in refractory focal epilepsy and at-home treatment of refractory depression.
The Goodwin team was led by Michael Bison, Patricia Mets, Daniel Hughes, and Wynn Stateman, with assistance from Alexandra Haas and Maggie Beale-Wirsing (Corporate); Dan Karelitz (Tax); Richard Matheny, James Brower, and Ce Li (Global Trade); Alexandra Denniston (ERISA); and Larissa Baker.For more details, read the press release and articles in Endpoints, BioSpace, and MedCity News.